Patents Assigned to Peptech Limited
  • Publication number: 20110237780
    Abstract: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-?, the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein said variable domain comprises at least one complementarity determining region (CDR) having a sequence derived from a New World primate.
    Type: Application
    Filed: January 18, 2011
    Publication date: September 29, 2011
    Applicant: Peptech Limited
    Inventors: Benjamin P. Woolven, Ian M. Tomlinson, Jennifer A. Lee, Anthony G. Doyle, Philip A. Jennings
  • Publication number: 20080095767
    Abstract: The present invention provides an antibody or antigen-binding portion thereof having a variable region comprising at least two complementarity determining regions (CDRs) and at least three framework regions. The the framework regions are, or are derived from New World primate framework regions, and at least one of the CDRs is a non-New World primate CDR.
    Type: Application
    Filed: August 1, 2007
    Publication date: April 24, 2008
    Applicant: Peptech Limited
    Inventors: Philip JENNINGS, Anthony Doyle, Adam Clarke, Robert Gay
  • Publication number: 20080031956
    Abstract: A pharmaceutical and/or veterinary formulation comprising about 2-30% (w/w) (on an active basis) of at least one active agent, about 0.5-20.0% (w/w) of a pore-forming agent comprising lecithin and an organic salt, and the balance stearin. Such formulations provide sustained release of the at least one active agent in humans and other animals for periods of 7 days up to about 2 years.
    Type: Application
    Filed: March 27, 2007
    Publication date: February 7, 2008
    Applicant: Peptech Limited
    Inventors: Timothy Trigg, John Walsh, Deborah Rathjen
  • Patent number: 7309689
    Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance sterin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.
    Type: Grant
    Filed: March 25, 2004
    Date of Patent: December 18, 2007
    Assignee: Peptech Limited
    Inventors: Timothy Elliot Trigg, John Desmond Walsh, Paul Adam Schober
  • Publication number: 20070202105
    Abstract: The present invention provides a domain antibody construct which binds to human TNF-?, the construct comprising: (a) a domain antibody (dAb) which binds to human TNF-?; (b) a modified hinge region sequence; (c) a human or primate heavy chain constant region sequence having a truncated CH1 domain of not more than 20 residues, wherein said modified hinge region sequence contains either a deletion or a single amino acid substitution of at least one cysteine residue which normally facilitates disulfide bond formation between heavy and light antibody chains.
    Type: Application
    Filed: February 1, 2007
    Publication date: August 30, 2007
    Applicant: Peptech Limited
    Inventors: ANTHONY DOYLE, Benjamin Woolven, Jennifer Lee, Ian Tomlinson, Philip Jennings
  • Publication number: 20070077248
    Abstract: The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumour and tumour regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumour cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.
    Type: Application
    Filed: February 23, 2006
    Publication date: April 5, 2007
    Applicant: Peptech Limited
    Inventors: Deborah Rathjen, Roger Aston
  • Publication number: 20060204499
    Abstract: The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumour and tumour regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumour cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.
    Type: Application
    Filed: May 8, 2006
    Publication date: September 14, 2006
    Applicant: Peptech Limited
    Inventors: Deborah Rathjen, Roger Aston
  • Publication number: 20050276854
    Abstract: A pharmaceutical and/or veterinary formulation comprising about 2-30% (w/w) (on an active basis) of at least one active agent, about 0.5-20.0% (w/w) of a pore-forming agent and the balance stearin. Such formulations provide sustained release of the at least one active agent in humans and other animals for periods of 7 days up to about 2 years.
    Type: Application
    Filed: January 25, 2005
    Publication date: December 15, 2005
    Applicant: Peptech Limited
    Inventors: Timothy Trigg, John Walsh, Deborah Rathjen
  • Patent number: 6924309
    Abstract: The present invention relates to compounds of the general formula: NO2-A-B wherein A is a saturated or unsaturated hydrocarbon chain of 14-26 carbon atoms and B is (CH2)n(COOH)m in which n is an integer from 0 to 2 and m is an integer from 0 to 2; or of general formula (I), wherein A? is a saturated or unsaturated hydrocarbon chain of 9-26 carbon atoms, X is oxygen or is absent and B? is (CH2)j(COOH)k in which j is an integer from 1 to 3 and k is 0 or 1; and the derivatives thereof in which the hydrocarbon chain includes one or more than one substitution selected from the group consisting of hydroxy, hydroperoxy, epoxy and peroxy. These compounds have biological activity, e.g. as anti-infective or anti-inflammatory agents.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: August 2, 2005
    Assignees: Children, Youth and Women's Health Service Incorporated, Peptech Limited
    Inventors: Antonio Ferrante, Christopher J. Easton, Ling Xia
  • Patent number: 6913761
    Abstract: A pharmaceutical and/or veterinary formulation comprising about 2-30% (w/w) (on an active basis) of at least one active agent, about 0.5-20.0% (w/w) of a pore-foaming agent and the balance stearin. Such formulations provided release of the at least one active agent in humans and other animals for periods of 7 days up to about 2 years.
    Type: Grant
    Filed: July 20, 1999
    Date of Patent: July 5, 2005
    Assignee: Peptech Limited
    Inventors: Timothy Elliot Trigg, John Desmond Walsh, Deborah Ann Rathjen
  • Publication number: 20040180832
    Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance sterin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.
    Type: Application
    Filed: March 25, 2004
    Publication date: September 16, 2004
    Applicant: Peptech Limited
    Inventors: Timothy Elliot Trigg, John Desmond Walsh, Paul Adam Schober
  • Patent number: 6777386
    Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance stearin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.
    Type: Grant
    Filed: November 26, 2001
    Date of Patent: August 17, 2004
    Assignee: Peptech Limited
    Inventors: Timothy Elliot Trigg, John Desmond Walsh, Paul Adam Schober
  • Patent number: 6593458
    Abstract: Provided are isolated antibodies or fragments thereof which bind a peptide consisting of residues Leu63-Phe64-Lys65-Gly66-Gln67-Gly68-Cys69-Pro70-Ser71-Thr72-His73-Val74-Leu75-Leu76-Thr77-His78-Thr79-Ile80-Ser81-Arg82-Ile83 (peptide 304) of mature human TNF-&agr;. The antibodies and fragments thereof may be used to identify antibodies capable of binding in the region of mature human TNF-&agr; of amino acid resides 63-83. Antibodies or fragments thereof which bind particular regions of mature human TNF-&agr; are shown to elicit particular biological activities dependent upon the particular region wherein binding occurs.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: July 15, 2003
    Assignee: Peptech Limited
    Inventors: Deborah Ann Rathjen, Roger Aston
  • Publication number: 20030064021
    Abstract: The present invention provides peptides capable of stimulating neutrophils. In particular, the peptides prime neutrophils for a respiratory burst following treatment with N-formyl-L-methionyl-L-leucyl-L-phenylalanine. The peptides have an amino acid sequence substantially corresponding to amino acids 54 to 94 of FIG. 1 or a part thereof. These peptides may also be used in the treatment of a subject having depressed neutrophil function.
    Type: Application
    Filed: April 10, 2002
    Publication date: April 3, 2003
    Applicant: Peptech Limited
    Inventors: Deborah Ann Rathjen, Antonio Ferrante
  • Patent number: 6498237
    Abstract: The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumour and tumour regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumour cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs) single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: December 24, 2002
    Assignee: Peptech Limited
    Inventors: Deborah Ann Rathjen, Roger Aston
  • Patent number: 6451983
    Abstract: The present invention relates to ligands which bind to human tumor necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumor and tumor regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumor cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs) single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: September 17, 2002
    Assignee: Peptech Limited
    Inventors: Deborah Ann Rathjen, Roger Aston
  • Patent number: 6448380
    Abstract: The present invention relates to ligands which bind to human tumor necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumor and tumor regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumor cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs) single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: September 10, 2002
    Assignee: Peptech Limited
    Inventors: Deborah Ann Rathjen, Roger Aston
  • Publication number: 20020052320
    Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15 % (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5 % (w/w) lecithin and the balance sterin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.
    Type: Application
    Filed: November 26, 2001
    Publication date: May 2, 2002
    Applicant: Peptech Limited
    Inventors: Timothy Elliot Trigg, John Desmond Walsh, Paul Adam Schober
  • Patent number: 6375928
    Abstract: The present invention provides peptides capable of stimulating neutrophils. In particular, the peptides prime neutrophils for a respiratory burst following treatment with N-formyl-L-methionyl-L-leucyl-L-phenylalanine. The peptides have an amino acid sequence substantially corresponding to amino acids 54 to 94 of FIG. 1 or a part thereof. These peptides may also be used in the treatment of a subject having depressed neutrophil function.
    Type: Grant
    Filed: June 21, 2000
    Date of Patent: April 23, 2002
    Assignee: Peptech Limited
    Inventors: Deborah Ann Rathjen, Antonio Ferrante
  • Patent number: 6211152
    Abstract: A pharmaceutical and/or veterinary formulation comprising deslorelin and an excipient, the formulation being characterised in that, in vitro, it releases deslorelin into phosphate buffered saline, as hereinbefore described, at 37° C. at a rate of about 2-80 &mgr;g/day for at least 200 days. The formulation may be used for prevention of reproductive function, particularly in dogs and cats, and for the treatment, particularly in humans, of prostate and breast cancer and other diseases and conditions where suppression of testosterone or estradiol levels is beneficial.
    Type: Grant
    Filed: February 17, 1999
    Date of Patent: April 3, 2001
    Assignee: Peptech Limited
    Inventors: John D. Walsh, Timothy E. Trigg